Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. CGEM
CGEM logo

CGEM

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CGEM News

Cullinan Therapeutics Q4 Earnings Miss Expectations

21h agoseekingalpha

Growth Prospects for the EGFR-NSCLC Market Analyzed

Feb 11 2026Newsfilter

Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More

Dec 08 2025Benzinga

Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients

Dec 08 2025Globenewswire

Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients

Dec 08 2025Newsfilter

Cullinan Secures FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML

Dec 01 2025NASDAQ.COM

Cullinan Receives FDA Fast Track Designation for CLN-049 in AML Treatment

Dec 01 2025Newsfilter

Cullinan Therapeutics Receives Fast Track Designation for CLN-049

Dec 01 2025NASDAQ.COM

Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday

Nov 24 2025Benzinga

LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading

Nov 24 2025Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for Cullinan Therapeutics, Increases Price Target to $26

Nov 20 2025Benzinga

Seven Tech Stocks Experience Significant Insider Selling Despite Price Increases

Oct 28 2025MarketWatch

Taiho Oncology and Cullinan Therapeutics Showcase Zipalertinib Data for NSCLC Patients with EGFR Mutations and Active Brain Metastases at ESMO Congress 2025

Oct 12 2025Newsfilter

Cullinan Therapeutics to Join Fireside Chat at Stifel's 2025 Virtual Forum on Immunology and Inflammation

Sep 12 2025Newsfilter

HC Wainwright & Co. Affirms Buy Rating for Cullinan Therapeutics, Keeps $24 Price Target Intact

Sep 12 2025Benzinga

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Sep 09 2025PRnewswire